The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
( 111 ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
Abstract
PURPOSE: Standard diagnostic methods are limited for detecting distant metastases in patients with prostate cancer in whom the only evidence of disease after radical prostatectomy is a detectable prostate specific antigen (PSA) level. We evaluated the role of immunoscintigraphy with the radiolabeled monoclonal antibody, 111indium ((111)In)-capromab pendetide, to differentiate between local and distant recurrence in this patient population. MATERIALS AND METHODS: We enrolled 183 men who had undergone radical prostatectomy in whom PSA later increased. Gamma camera images were acquired twice after infusion of a single dose of (111)In-capromab pendetide. RESULTS: Immunoscintigraphy revealed disease in 108 of 181 patients (60%) with interpretable scans. The antibody was localized most frequently to the prostatic fossa (34% of the cases), abdominal lymph nodes (23%) and pelvic lymph nodes (22%). Of the 181 men the scan localized the antibody outside the prostatic fossa in 42%. Half of the positive localizations in the fossa were confirmed by biopsy. CONCLUSIONS: These findings suggest that immunoscintigraphy with (111)In-capromab pendetide can assist in determining the extent of disease in patients who have increasing PSA after prostatectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Cited by
Tagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N. H., Osborne, J., Goldsmith, S. J., Larson, S., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER
MOUL, J. W. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67511-8 · Cited by 350
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.154 · Cited by 313
Cimitan, M., Bortolus, R., Morassut, S., Canzonieri, V., Garbeglio, A., Baresic, T., Borsatti, E., Drigo, A., & Trovò, M. G. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0150-2 · Cited by 312
Minner, S., Wittmer, C., Graefen, M., Salomon, G., Steuber, T., Haese, A., Huland, H., Bokemeyer, C., Yekebas, E., Dierlamm, J., et al. (2011) · The Prostate · doi:10.1002/pros.21241 · Cited by 284
Metadata
- Authors
- KAHN, D., WILLIAMS, R. D., MANYAK, M. J., HASEMAN, M. K., SELDIN, D. W., LIBERTINO, J. A., MAGUIRE, R. T., & The ProstaScint Study Group
- Venue
- Journal of Urology
- Published
- 1998-06
- Volume
- 159
- Issue
- 6
- Pages
- 2041-2047
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2089372512
- Cited by
- 170
- References
- 1
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ( 111 ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. https://app.cochat.ai/papers/10.1016/s0022-5347(01)63239-7
- The paper
- KAHN, D., WILLIAMS, R. D., MANYAK, M. J., HASEMAN, M. K., SELDIN, D. W., LIBERTINO, J. A., MAGUIRE, R. T., & The ProstaScint Study Group. (1998). ( 111 ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. Journal of Urology. https://doi.org/10.1016/s0022-5347(01)63239-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.